Consensus statementAdvanced Parkinson's disease: Clinical characteristics and treatment. Part IIEnfermedad de Parkinson avanzada. Características clínicas y tratamiento. Parte II☆

Introduction Many patients who have had Parkinson's disease (PD) for several years will present severe motor fluctuations and dyskinesias which require more aggressive therapies. The different approaches which are now available include deep brain stimulation of the subthalamic nucleus or medial globus pallidus, subcutaneous infusion of apomorphine, and intestinal infusion of levodopa–carbidopa.

[1]  J. Régis,et al.  Addiction in Parkinson's disease: Impact of subthalamic nucleus deep brain stimulation , 2005, Movement disorders : official journal of the Movement Disorder Society.

[2]  Y. Agid,et al.  Pathological gambling in Parkinson's disease improves on chronic subthalamic nucleus stimulation , 2006, Movement disorders : official journal of the Movement Disorder Society.

[3]  C. Tanner,et al.  Early dopaminergic drug-induced hallucinations in parkinsonian patients , 1998, Neurology.

[4]  Natalie E. Allen,et al.  The effects of an exercise program on fall risk factors in people with Parkinson's disease: A randomized controlled trial , 2010, Movement disorders : official journal of the Movement Disorder Society.

[5]  Claire Ballinger,et al.  A randomised controlled trial of a home based exercise programme to reduce the risk of falling among people with Parkinson’s disease , 2006, Journal of Neurology, Neurosurgery & Psychiatry.

[6]  K. Leenders,et al.  Transcutaneous port for continuous duodenal levodopa/carbidopa administration in Parkinson's disease , 2011, Movement disorders : official journal of the Movement Disorder Society.

[7]  R. Brown,et al.  Apathy in Parkinson’s disease , 2002, Journal of neurology, neurosurgery, and psychiatry.

[8]  Y. Agid,et al.  Long‐term results of a multicenter study on subthalamic and pallidal stimulation in Parkinson's disease , 2010, Movement disorders : official journal of the Movement Disorder Society.

[9]  P. Ewings,et al.  An exercise intervention to prevent falls in people with Parkinson's disease: a pragmatic randomised controlled trial , 2011, Journal of Neurology, Neurosurgery & Psychiatry.

[10]  C. Tanner,et al.  Serotonin syndrome and the combined use of deprenyl and an antidepressant in Parkinson's disease , 1997, Neurology.

[11]  Lynn Rochester,et al.  The Short-Term Effects of Different Cueing Modalities on Turn Speed in People with Parkinson’s Disease , 2009, Neurorehabilitation and neural repair.

[12]  C. Pont‐Sunyer,et al.  Eighteen month study of continuous intraduodenal levodopa infusion in patients with advanced Parkinson's disease: impact on control of fluctuations and quality of life. , 2010, Parkinsonism & related disorders.

[13]  [Behavioral disorders in Parkinson's disease: from pathophysiology to the mastery of dopaminergic treatment]. , 2010, Revue neurologique.

[14]  Clinical observation of combined acupuncture and herbs in treating Parkinson’s disease , 2009 .

[15]  T. Anderson,et al.  Rotigotine Effects on Early Morning Motor Function and Sleep in Parkinson's Disease: A Double-Blind, Randomized, pLacebo-Controlled Study (RECOVER) , 2010, Movement disorders : official journal of the Movement Disorder Society.

[16]  Daniel Weintraub,et al.  Psychosis in Parkinson's disease without dementia: Common and comorbid with other non‐motor symptoms , 2012, Movement disorders : official journal of the Movement Disorder Society.

[17]  P. Mertens,et al.  Bilateral subthalamic nucleus stimulation in advanced Parkinson’s disease: Five year follow-up , 2009, Journal of Neurology.

[18]  M. Onofrj,et al.  Pathological gambling in Parkinson disease is reduced by amantadine , 2010, Annals of neurology.

[19]  E. Tolosa,et al.  Pramipexole for the treatment of depressive symptoms in patients with Parkinson's disease: a randomised, double-blind, placebo-controlled trial , 2010, The Lancet Neurology.

[20]  C. Clarke,et al.  Meta‐analysis of the comparative efficacy and safety of adjuvant treatment to levodopa in later Parkinson's disease , 2011, Movement disorders : official journal of the Movement Disorder Society.

[21]  O. Lindvall,et al.  Pen injected apomorphine against off phenomena in late Parkinson's disease: a double blind, placebo controlled study. , 1995, Journal of neurology, neurosurgery, and psychiatry.

[22]  M. Dafotakis,et al.  Transdermal dopaminergic stimulation with rotigotine in Parkinsonian akinetic crisis , 2009, Journal of Clinical Neuroscience.

[23]  A. Siderowf,et al.  Long‐term follow‐up of impulse control disorders in Parkinson's disease , 2008, Movement disorders : official journal of the Movement Disorder Society.

[24]  W. Weiner,et al.  Practice Parameter: Neuroprotective strategies and alternative therapies for Parkinson disease (an evidence-based review): Report of the Quality Standards Subcommittee of the American Academy of Neurology , 2006, Neurology.

[25]  H. Bjartmarz,et al.  Intracerebral Infections as a Complication of Deep Brain Stimulation , 2012, Stereotactic and Functional Neurosurgery.

[26]  Nir Giladi,et al.  Rater-blinded, Prospective Comparison: Quetiapine Versus Clozapine for Parkinson's Disease Psychosis , 2006, Clinical neuropharmacology.

[27]  J. Langston,et al.  Oral levodopa/carbidopa solution versus tablets in Parkinson's patients with severe fluctuations , 1993, Neurology.

[28]  L. Kristjanson,et al.  Would people with Parkinson's disease benefit from palliative care? , 2006, Palliative medicine.

[29]  Y. Agid,et al.  Long‐term effects of pallidal or subthalamic deep brain stimulation on quality of life in Parkinson's disease , 2009, Movement disorders : official journal of the Movement Disorder Society.

[30]  P. Hogarth,et al.  Pallidal vs subthalamic nucleus deep brain stimulation in Parkinson disease. , 2005, Archives of neurology.

[31]  M. Hely,et al.  Sydney multicenter study of Parkinson's disease: Non‐L‐dopa–responsive problems dominate at 15 years , 2005, Movement disorders : official journal of the Movement Disorder Society.

[32]  Andrew J Lees,et al.  Apomorphine monotherapy in the treatment of refractory motor complications of Parkinson's disease: Long‐term follow‐up study of 64 patients , 2002, Movement disorders : official journal of the Movement Disorder Society.

[33]  K. Chaudhuri,et al.  Non-motor symptoms of Parkinson's disease: diagnosis and management , 2006, The Lancet Neurology.

[34]  D. Aarsland,et al.  A systematic review of prevalence studies of dementia in Parkinson's disease , 2005, Movement disorders : official journal of the Movement Disorder Society.

[35]  L. Tremblay,et al.  Non-motor dopamine withdrawal syndrome after surgery for Parkinson's disease: predictors and underlying mesolimbic denervation. , 2010, Brain : a journal of neurology.

[36]  R. Esselink,et al.  Unilateral pallidotomy versus bilateral subthalamic nucleus stimulation in Parkinson’s disease: one year follow-up of a randomised observer-blind multi centre trial , 2006, Acta Neurochirurgica.

[37]  M. Vassallo,et al.  Diagnostic and therapeutic value of apomorphine in Parkinsonian patients , 2004, International journal of clinical practice.

[38]  Dag Aarsland,et al.  Depression in Parkinson disease—epidemiology, mechanisms and management , 2011, Nature Reviews Neurology.

[39]  Q. Almeida,et al.  Symptom and gait changes after sensory attention focused exercise vs aerobic training in Parkinson's disease , 2009, Movement disorders : official journal of the Movement Disorder Society.

[40]  A. Lang,et al.  Ten-year outcome of subthalamic stimulation in Parkinson disease: a blinded evaluation. , 2011, Archives of neurology.

[41]  S Minoshima,et al.  Diagnosis and management of dementia with Lewy bodies , 2005, Neurology.

[42]  A. Lang,et al.  Amantadine use associated with impulse control disorders in Parkinson disease in cross‐sectional study , 2010, Annals of neurology.

[43]  P. Leigh,et al.  Use of apomorphine in parkinsonian patients with neuropsychiatric complications to oral treatment. , 1997, Parkinsonism & related disorders.

[44]  J. Cummings,et al.  Range of neuropsychiatric disturbances in patients with Parkinson’s disease , 1999, Journal of neurology, neurosurgery, and psychiatry.

[45]  Grant D. Huang,et al.  Pallidal versus subthalamic deep-brain stimulation for Parkinson's disease. , 2010, The New England journal of medicine.

[46]  D. Nyholm,et al.  Comparison of apomorphine and levodopa infusions in four patients with Parkinson’s disease with symptom fluctuations , 2009, Acta neurologica Scandinavica.

[47]  W. Poewe,et al.  Milestones in Parkinson's disease therapeutics , 2011, Movement disorders : official journal of the Movement Disorder Society.

[48]  Angelo Antonini,et al.  Apomorphine and levodopa infusion therapies for advanced Parkinson’s disease: selection criteria and patient management , 2009, Expert review of neurotherapeutics.

[49]  Tung-Wu Lu,et al.  Effects of Virtual Reality–Augmented Balance Training on Sensory Organization and Attentional Demand for Postural Control in People With Parkinson Disease: A Randomized Controlled Trial , 2011, Physical Therapy.

[50]  L. Metman,et al.  Fluctuations in plasma levodopa and motor responses with liquid and tablet levodopa/carbidopa , 1994, Movement disorders : official journal of the Movement Disorder Society.

[51]  J. Cummings,et al.  Depression and Parkinson's disease: a review. , 1992, The American journal of psychiatry.

[52]  G. Lopez,et al.  Nonmotor fluctuations in Parkinson's disease: Clinical spectrum and classification , 2010, Journal of the Neurological Sciences.

[53]  Rinne Uk,et al.  A double-blind pharmacokinetic and clinical dose-response study of entacapone as an adjuvant to levodopa therapy in advanced Parkinson's disease. , 1996 .

[54]  P. Kempster,et al.  Patterns of levodopa response in Parkinson's disease: a clinico-pathological study. , 2007, Brain : a journal of neurology.

[55]  K. Chaudhuri,et al.  SUBCUTANEOUS APOMORPHINE FOR ON-OFF OSCILLATIONS IN PARKINSON'S DISEASE , 1988, The Lancet.

[56]  A Albanese,et al.  Cognitive and behavioural effects of chronic stimulation of the subthalamic nucleus in patients with Parkinson’s disease , 2003, Journal of neurology, neurosurgery, and psychiatry.

[57]  Jan Kassubek,et al.  Transdermal rotigotine for the perioperative management of Parkinson’s disease , 2010, Journal of Neural Transmission.

[58]  P. Odin,et al.  Levodopa–carbidopa intestinal gel for treatment of advanced Parkinson’s disease , 2011, Current medical research and opinion.

[59]  Silvia Vázquez-Fernández del Pozo,et al.  Motor complications in Parkinson's disease: Ten year follow‐up study , 2010, Movement disorders : official journal of the Movement Disorder Society.

[60]  I. Shoulson,et al.  Duodenal delivery of levodopa for on‐off fluctuations in parkinsonism: Preliminary observations , 1986, Annals of neurology.

[61]  M. Kurth.  Using Liquid Levodopa in the Treatment of Parkinson’s Disease , 1997, Drugs & aging.

[62]  P. Stanzione,et al.  Bilateral deep brain stimulation of the pedunculopontine and subthalamic nuclei in severe Parkinson's disease. , 2007, Brain : a journal of neurology.

[63]  M. Okun,et al.  Psychosis in Parkinson’s Disease , 2004, Journal of geriatric psychiatry and neurology.

[64]  E. Tolosa,et al.  Comparative cognitive effects of bilateral subthalamic stimulation and subcutaneous continuous infusion of apomorphine in Parkinson's disease , 2004, Movement disorders : official journal of the Movement Disorder Society.

[65]  Angelo Antonini,et al.  A 5-year prospective assessment of advanced Parkinson disease patients treated with subcutaneous apomorphine infusion or deep brain stimulation , 2011, Journal of Neurology.

[66]  R. Fimmers,et al.  Qigong exercise for the symptoms of Parkinson's disease: A randomized, controlled pilot study , 2006, Movement disorders : official journal of the Movement Disorder Society.

[67]  S. Galandiuk,et al.  Meta‐analysis: antibiotic prophylaxis to prevent peristomal infection following percutaneous endoscopic gastrostomy , 2007, Alimentary pharmacology & therapeutics.

[68]  Y. Agid,et al.  Mortality in patients with Parkinson's disease treated by stimulation of the subthalamic nucleus , 2007, Movement disorders : official journal of the Movement Disorder Society.

[69]  H. Russmann,et al.  Subthalamic nucleus deep brain stimulation in Parkinson disease patients over age 70 years , 2004, Neurology.

[70]  L. Hansson,et al.  Long‐term intraduodenal infusion of a water based levodopa‐carbidopa dispersion in very advanced Parkinson's disease , 1998, Acta neurologica Scandinavica.

[71]  J L Vitek,et al.  Mood changes with deep brain stimulation of STN and GPi: results of a pilot study , 2003, Journal of neurology, neurosurgery, and psychiatry.

[72]  K. Østergaard,et al.  Evolution of Parkinson's disease during 4 years of bilateral deep brain stimulation of the subthalamic nucleus , 2006, Movement disorders : official journal of the Movement Disorder Society.

[73]  G. Deuschl,et al.  Subthalamic nucleus deep brain stimulation: Summary and meta‐analysis of outcomes , 2006, Movement disorders : official journal of the Movement Disorder Society.

[74]  H. Erdem,et al.  The effects of incremental speed-dependent treadmill training on postural instability and fear of falling in Parkinson's disease , 2007, Clinical rehabilitation.

[75]  Antonio Daniele,et al.  Treatment of motor and non-motor features of Parkinson's disease with deep brain stimulation , 2012, The Lancet Neurology.

[76]  G. Stebbins,et al.  Levodopa stability in solution: Time course, environmental effects, and practical recommendations for clinical use , 1996, Movement disorders : official journal of the Movement Disorder Society.

[77]  D. Nyholm.  Enteral levodopa/carbidopa gel infusion for the treatment of motor fluctuations and dyskinesias in advanced Parkinson’s disease , 2006, Expert review of neurotherapeutics.

[78]  A. Hughes,et al.  Subcutaneous apomorphine in parkinson's disease: Response to chronic administration for up to five years , 1993, Movement disorders : official journal of the Movement Disorder Society.

[79]  I G McKeith,et al.  Rivastigmine in the treatment of parkinsonian psychosis and cognitive impairment: Preliminary findings from an open trial , 2001, Movement disorders : official journal of the Movement Disorder Society.

[80]  A. Benabid,et al.  Effects of subthalamic nucleus stimulation and levodopa on freezing of gait in Parkinson disease , 2008, Neurology.

[81]  R. Marconi,et al.  Quetiapine and Clozapine in Parkinsonian Patients With Dopaminergic Psychosis , 2004, Clinical neuropharmacology.

[82]  Gammon M Earhart,et al.  Effects of dance on movement control in Parkinson's disease: a comparison of Argentine tango and American ballroom. , 2009, Journal of rehabilitation medicine.

[83]  M. Nirenberg,et al.  Dopamine agonist withdrawal syndrome in Parkinson disease. , 2010, Archives of neurology.

[84]  G. Deuschl,et al.  A randomized trial of deep-brain stimulation for Parkinson's disease. , 2006, The New England journal of medicine.

[85]  D. Santos-García,et al.  Suicide following duodenal levodopa infusion for Parkinson's disease , 2009, Movement disorders : official journal of the Movement Disorder Society.

[86]  L. Lopiano,et al.  Duodenal levodopa infusion for advanced Parkinson's disease: 12‐month treatment outcome , 2007, Movement disorders : official journal of the Movement Disorder Society.

[87]  Terry D Ellis,et al.  Changes in walking activity and endurance following rehabilitation for people with Parkinson disease. , 2009, Archives of physical medicine and rehabilitation.

[88]  M. Okun,et al.  Aspiration and swallowing in Parkinson disease and rehabilitation with EMST , 2010, Neurology.

[89]  W. Weiner,et al.  Comorbidity of the nonmotor symptoms of Parkinson's disease , 2001, Movement disorders : official journal of the Movement Disorder Society.

[90]  A. Lees,et al.  SUBCUTANEOUS APOMORPHINE IN PARKINSONIAN ON-OFF OSCILLATIONS , 1988, The Lancet.

[91]  J. Jankovic,et al.  Cognitive declines following bilateral subthalamic nucleus deep brain stimulation for the treatment of Parkinson’s disease , 2007, Journal of Neurology, Neurosurgery, and Psychiatry.

[92]  D. Nyholm,et al.  Duodenal levodopa infusion in Parkinson's disease – long‐term experience , 2001, Acta neurologica Scandinavica.

[93]  Y Agid,et al.  Neurosurgery in Parkinson disease , 2006, Neurology.

[94]  W. Koller,et al.  Randomized trial of tolcapone versus pergolide as add‐on to levodopa therapy in Parkinson's disease patients with motor fluctuations , 2001, Movement disorders : official journal of the Movement Disorder Society.

[95]  R. de la Fuente-Fernández,et al.  Long‐term exposure to duodenal levodopa/carbidopa infusion therapy improves quality of life in relation especially to mobility, activities of daily living, and emotional well‐being , 2012, Acta neurologica Scandinavica.

[96]  A. Bentivoglio,et al.  Replacement of dopaminergic medication with subthalamic nucleus stimulation in Parkinson's disease: Long‐term observation , 2009, Movement disorders : official journal of the Movement Disorder Society.

[97]  A. Benabid,et al.  Five-year follow-up of bilateral stimulation of the subthalamic nucleus in advanced Parkinson's disease. , 2003, The New England journal of medicine.

[98]  D. Wade,et al.  Rehabilitation with mental practice has similar effects on mobility as rehabilitation with relaxation in people with Parkinson's disease: a multicentre randomised trial. , 2011, Journal of physiotherapy.

[99]  Yea-Ru Yang,et al.  Downhill Walking Training in Individuals with Parkinson's Disease: A Randomized Controlled Trial , 2010, American journal of physical medicine & rehabilitation.

[100]  Maladie de Parkinson : de la physiopathologie des troubles psychiques à la maîtrise du traitement dopaminergique , 2010 .

[101]  Sarah A. Spinier,et al.  Hyponatremia Associated with Selective Serotonin-Reuptake Inhibitors in Older Adults , 2006, The Annals of pharmacotherapy.

[102]  H. Lennernäs,et al.  Optimizing Levodopa Pharmacokinetics: Intestinal Infusion Versus Oral Sustained-Release Tablets , 2003, Clinical neuropharmacology.

[103]  Y. Michotte,et al.  Clinical and pharmacokinetic comparison of oral and duodenal delivery of levodopa/carbidopa in patients with Parkinson's disease with a fluctuating response to levodopa , 2004, European Journal of Clinical Pharmacology.

[104]  J. Langston,et al.  Double‐blind, placebo‐controlled, crossover study of duodenal infusion of levodopa/carbidopa in Parkinson's disease patients with 'on‐off' fluctuations , 1993, Neurology.

[105]  Madeleine. E. Hackney,et al.  Effects of Dance on Gait and Balance in Parkinson’s Disease: A Comparison of Partnered and Nonpartnered Dance Movement , 2010, Neurorehabilitation and neural repair.

[106]  H. Freund,et al.  Long‐term results of bilateral pallidal stimulation in Parkinson's disease , 2004, Annals of neurology.

[107]  H M M Smeding,et al.  Pathological Gambling after bilateral STN stimulation in Parkinson disease , 2008 .

[108]  O. Suchowersky,et al.  Neuropathy as a potential complication of levodopa use in Parkinson's disease , 2008, Movement disorders : official journal of the Movement Disorder Society.

[109]  D. Tompson,et al.  Pharmacokinetic and Pharmacodynamic Comparison of Ropinirole 24-Hour Prolonged Release and Ropinirole Immediate Release in Patients With Parkinson's Disease , 2009, Clinical neuropharmacology.

[110]  N. Matsukawa,et al.  Complications of subthalamic nucleus stimulation in Parkinson's disease. , 2011, Neurologia medico-chirurgica.

[111]  D. Deleu,et al.  Subcutaneous Apomorphine , 2004, Drugs & aging.

[112]  A. Schapira,et al.  PREPARED: Comparison of prolonged and immediate release ropinirole in advanced Parkinson's disease , 2011, Movement disorders : official journal of the Movement Disorder Society.

[113]  E. Perry,et al.  CORTICAL CHOLINERGIC DEFICIT IN MENTALLY IMPAIRED PARKINSONIAN PATIENTS , 1983, The Lancet.

[114]  Lynn Rochester,et al.  Evidence for motor learning in Parkinson's disease: Acquisition, automaticity and retention of cued gait performance after training with external rhythmical cues , 2010, Brain Research.

[115]  F. Mastaglia,et al.  Globus pallidus stimulation improves both motor and nonmotor aspects of quality of life in advanced Parkinson's disease , 2007, Movement disorders : official journal of the Movement Disorder Society.

[116]  D. Burn,et al.  Parkinson's disease: The quintessential neuropsychiatric disorder , 2011, Movement disorders : official journal of the Movement Disorder Society.

[117]  E. Tolosa,et al.  Efficacy of pramipexole and transdermal rotigotine in advanced Parkinson's disease: a double-blind, double-dummy, randomised controlled trial , 2007, The Lancet Neurology.

[118]  A. Lang,et al.  Impulse control disorders in Parkinson disease: a cross-sectional study of 3090 patients. , 2010, Archives of neurology.

[119]  C. Lyketsos,et al.  Randomized placebo‐controlled trial of donepezil in cognitive impairment in Parkinson's disease , 2004, International journal of geriatric psychiatry.

[120]  D. Nyholm,et al.  Duodenal levodopa infusion monotherapy vs oral polypharmacy in advanced Parkinson disease , 2005, Neurology.

[121]  A. Bentivoglio,et al.  Motor and cognitive outcome in patients with Parkinson's disease 8 years after subthalamic implants. , 2010, Brain : a journal of neurology.

[122]  L. Defebvre,et al.  Comparison of desipramine and citalopram treatments for depression in Parkinson's disease: A double‐blind, randomized, placebo‐controlled study , 2008, Movement disorders : official journal of the Movement Disorder Society.

[123]  D. Devos.  Patient profile, indications, efficacy and safety of duodenal levodopa infusion in advanced Parkinson's disease , 2009, Movement disorders : official journal of the Movement Disorder Society.

[124]  J. Carter,et al.  PARKINSON DISEASE AT THE END OF LIFE: CAREGIVER PERSPECTIVES , 2007, Neurology.

[125]  A J Lees,et al.  Continuous subcutaneous waking day apomorphine in the long term treatment of levodopa induced interdose dyskinesias in Parkinson’s disease , 1998, Journal of neurology, neurosurgery, and psychiatry.

[126]  T. Lewander,et al.  Enteral Levodopa/Carbidopa Infusion in Advanced Parkinson Disease: Long-term Exposure , 2008, Clinical neuropharmacology.

[127]  Yasin Temel,et al.  Behavioural changes after bilateral subthalamic stimulation in advanced Parkinson disease: a systematic review. , 2006, Parkinsonism & related disorders.

[128]  R. de la Fuente-Fernández,et al.  Duodenal levodopa/carbidopa infusion therapy in patients with advanced Parkinson’s disease leads to improvement in caregivers’ stress and burden , 2012, European journal of neurology.

[129]  M. Morris,et al.  A randomized controlled trial of movement strategies compared with exercise for people with Parkinson's disease , 2009, Movement disorders : official journal of the Movement Disorder Society.

[130]  Y. Agid,et al.  Neurosurgery at an earlier stage of Parkinson disease , 2007, Neurology.

[131]  G. Kwakkel,et al.  Does Cueing Training Improve Physical Activity in Patients With Parkinson’s Disease? , 2010, Neurorehabilitation and neural repair.

[132]  J. Friedman,et al.  Long‐term outcome of quetiapine use for psychosis among parkinsonian patients , 2003, Movement disorders : official journal of the Movement Disorder Society.

[133]  Ş. Kutlay,et al.  Does Treadmill Training Improve Lower-Extremity Tasks in Parkinson Disease? A Randomized Controlled Trial , 2008, Clinical journal of sport medicine : official journal of the Canadian Academy of Sport Medicine.

[134]  P. Odin,et al.  Subcutaneous apomorphine in late stage Parkinson’s disease: a long term follow up , 1998, Journal of neurology, neurosurgery, and psychiatry.

[135]  Elizabeth Eckstrom,et al.  Tai chi and postural stability in patients with Parkinson's disease. , 2012, The New England journal of medicine.

[136]  S. Factor,et al.  A randomized, double-blind, placebo-controlled trial of subcutaneously injected apomorphine for parkinsonian off-state events. , 2001, Archives of neurology.

[137]  J. Kulisevsky,et al.  Cognitive impairment and dementia in Parkinson's disease , 2012, Neurobiology of Disease.

[138]  M. Canesi,et al.  Duodenal Levodopa Infusion Improves Quality of Life in Advanced Parkinson’s Disease , 2008, Neurodegenerative Diseases.

[139]  E. Ernst,et al.  Effectiveness of acupuncture for Parkinson's disease: A systematic review , 2008, Movement disorders : official journal of the Movement Disorder Society.

[140]  Adrian Danek,et al.  Neuropsychological and psychiatric changes after deep brain stimulation for Parkinson's disease: a randomised, multicentre study , 2008, The Lancet Neurology.

[141]  J. Friedman,et al.  Treatment of Psychosis in Parkinson’s Disease , 2003, Drug safety.

[142]  Roy W Jones,et al.  Memantine for patients with Parkinson's disease dementia or dementia with Lewy bodies: a randomised, double-blind, placebo-controlled trial , 2010, The Lancet Neurology.

[143]  A. Berardelli,et al.  Dual dopamine agonist treatment in Parkinson’s disease , 2003, Journal of Neurology.

[144]  W. Oertel,et al.  Long‐term efficacy and safety of pramipexole in advanced Parkinson's disease: Results from a European multicenter trial , 2005, Movement disorders : official journal of the Movement Disorder Society.

[145]  N. Earl,et al.  Early treatment benefits of ropinirole prolonged release in Parkinson's disease patients with motor fluctuations , 2010, Movement disorders : official journal of the Movement Disorder Society.

[146]  R. Duvoisin,et al.  Treatment of parkinsonism with levodopa. , 1969, Archives of neurology.

[147]  Lorys Castelli,et al.  Deep brain stimulation of the subthalamic nucleus in Parkinson's disease: comparison of pre- and postoperative neuropsychological evaluation , 2001, Journal of the Neurological Sciences.

[148]  Charles Howard Adler,et al.  Randomized, Placebo-Controlled Study of Tolcapone in Patients With Fluctuating Parkinson Disease Treated With Levodopa-Carbidopa , 1998 .

[149]  D. Koziorowski,et al.  Levodopa “drug holiday” with amantadine infusions as a treatment of complications in Parkinson's disease , 2007, Movement disorders : official journal of the Movement Disorder Society.

[150]  W Poewe,et al.  Rasagiline as an adjunct to levodopa in patients with Parkinson's disease and motor fluctuations (LARGO, Lasting effect in Adjunct therapy with Rasagiline Given Once daily, study): a randomised, double-blind, parallel-group trial , 2005, The Lancet.

[151]  R. Uitti,et al.  Timely levodopa (LD) administration prolongs survival in Parkinson's disease. , 1997, Parkinsonism & related disorders.

[152]  G. Kwakkel,et al.  Cueing training in the home improves gait-related mobility in Parkinson’s disease: the RESCUE trial , 2007, Journal of Neurology, Neurosurgery & Psychiatry.

[153]  O. Rascol,et al.  Extended-release pramipexole in advanced Parkinson disease , 2011, Neurology.

[154]  Ioannis U Isaias,et al.  Brain networks underlining verbal fluency decline during STN-DBS in Parkinson's disease: an ECD-SPECT study. , 2007, Parkinsonism & related disorders.

[155]  Gammon M Earhart,et al.  Tai Chi improves balance and mobility in people with Parkinson disease. , 2008, Gait & posture.

[156]  K. Lyons,et al.  Advanced Parkinson disease treated with rotigotine transdermal system , 2007, Neurology.

[157]  P. Krack,et al.  Deep-brain stimulation of the subthalamic nucleus or the pars interna of the globus pallidus in Parkinson's disease. , 2001, The New England journal of medicine.

[158]  G. Cossu,et al.  Reversible encephalopathy and axonal neuropathy in Parkinson's disease during duodopa therapy , 2009, Movement disorders : official journal of the Movement Disorder Society.

[159]  L. Metman,et al.  Deep brain stimulation for Parkinson's disease: Prevalence of adverse events and need for standardized reporting , 2008, Movement disorders : official journal of the Movement Disorder Society.

[160]  E. Tolosa,et al.  Clinical diagnostic criteria for dementia associated with Parkinson's disease , 2007, Movement disorders : official journal of the Movement Disorder Society.

[161]  W. Oertel,et al.  Continuous Jejunal Levodopa Infusion in Patients With Advanced Parkinson Disease: Practical Aspects and Outcome of Motor and Non-motor Complications , 2008, Clinical neuropharmacology.

[162]  G K Wenning,et al.  Apomorphine: An underutilized therapy for Parkinson's disease , 2000, Movement disorders : official journal of the Movement Disorder Society.

[163]  K. Lyons,et al.  Ropinirole 24-hour prolonged release , 2007, Neurology.

[164]  J. Reid,et al.  Idiopathic Parkinsonism Treated with an Extracerebral Decarboxylase Inhibitor in Combination with Levodopa , 1971, British medical journal.

[165]  D. Aarsland,et al.  Donepezil for cognitive impairment in Parkinson's disease: a randomised controlled study , 2002, Journal of neurology, neurosurgery, and psychiatry.

[166]  G. Deuschl,et al.  Thirty days complication rate following surgery performed for deep‐brain‐stimulation , 2007, Movement disorders : official journal of the Movement Disorder Society.

[167]  W. Poewe,et al.  The Movement Disorder Society Evidence‐Based Medicine Review Update: Treatments for the non‐motor symptoms of Parkinson's disease , 2011, Movement disorders : official journal of the Movement Disorder Society.

[168]  Antonio Daniele,et al.  Transient mania with hypersexuality after surgery for high frequency stimulation of the subthalamic nucleus in Parkinson's disease , 2002, Movement disorders : official journal of the Movement Disorder Society.

[169]  S. Buyske,et al.  A controlled trial of antidepressants in patients with Parkinson disease and depression , 2009, Neurology.

[170]  D. Berg,et al.  Progression of Parkinson's disease in the clinical phase: potential markers , 2009, The Lancet Neurology.

[171]  G. Stebbins,et al.  Visual plus nonvisual hallucinations in Parkinson's disease: Development and evolution over 10 years , 2011, Movement disorders : official journal of the Movement Disorder Society.

[172]  C. Mariani,et al.  Clinical and neuropsychological follow up at 12 months in patients with complicated Parkinson’s disease treated with subcutaneous apomorphine infusion or deep brain stimulation of the subthalamic nucleus , 2006, Journal of Neurology, Neurosurgery & Psychiatry.

[173]  B. Bloem,et al.  Evidence‐based analysis of physical therapy in Parkinson's disease with recommendations for practice and research , 2007, Movement disorders : official journal of the Movement Disorder Society.

[174]  S. Countryman,et al.  Changes in vocal loudness following intensive voice treatment (LSVT®) in individuals with Parkinson's disease: A comparison with untreated patients and normal age‐matched controls , 2001, Movement disorders : official journal of the Movement Disorder Society.

[175]  M. Rizzone,et al.  Beyond nine years of continuous subthalamic nucleus deep brain stimulation in Parkinson's disease , 2011, Movement disorders : official journal of the Movement Disorder Society.

[176]  A. Benabid,et al.  Long term effects of bilateral subthalamic nucleus stimulation on cognitive function, mood, and behaviour in Parkinson’s disease , 2004, Journal of Neurology, Neurosurgery & Psychiatry.

[177]  F. Horak,et al.  A meta-regression of the long-term effects of deep brain stimulation on balance and gait in PD , 2010, Neurology.

[178]  J. Carter,et al.  Neurologic disease at the end of life: caregiver descriptions of Parkinson disease and amyotrophic lateral sclerosis. , 2008, Journal of palliative medicine.

[179]  A. Lawrence,et al.  Dopamine dysregulation syndrome, impulse control disorders and punding after deep brain stimulation surgery for Parkinson’s disease , 2009, Journal of Clinical Neuroscience.

[180]  D. Nyholm,et al.  Long-term 24-h levodopa/carbidopa gel infusion in Parkinson's disease. , 2012, Parkinsonism & related disorders.

[181]  J. Kulisevsky,et al.  Acute effects of immediate and controlled‐release levodopa on mood in Parkinson's disease: A double‐blind study , 2007, Movement disorders : official journal of the Movement Disorder Society.

[182]  A. Crawley,et al.  Donepezil for dementia in Parkinson’s disease: a randomised, double blind, placebo controlled, crossover study , 2005, Journal of Neurology, Neurosurgery & Psychiatry.

[183]  L. Kristjanson,et al.  Palliative care and support for people with neurodegenerative conditions and their carers. , 2006, International journal of palliative nursing.

[184]  R. Marconi,et al.  Continuous apomorphine infusion (CAI) and neuropsychiatric disorders in patients with advanced Parkinson's disease: a follow-up of two years. , 2004, Archives of gerontology and geriatrics. Supplement.

[185]  Ropinirole is effective on motor function when used as an adjunct to levodopa in Parkinson's disease: STRONG study , 2007, Movement disorders : official journal of the Movement Disorder Society.

[186]  Linda Tickle-Degnen,et al.  Self‐management rehabilitation and health‐related quality of life in Parkinson's disease: A randomized controlled trial , 2010, Movement disorders : official journal of the Movement Disorder Society.

[187]  Marten Munneke,et al.  Effects of stereotactic neurosurgery on postural instability and gait in Parkinson's disease , 2004, Movement disorders : official journal of the Movement Disorder Society.

[188]  E. Tolosa,et al.  When does Parkinson's disease begin? , 2009, Movement disorders : official journal of the Movement Disorder Society.

[189]  A L Benabid,et al.  Bilateral subthalamic or pallidal stimulation for Parkinson's disease affects neither memory nor executive functions: A consecutive series of 62 patients , 1999, Annals of neurology.

[190]  Ivan Rektor,et al.  Levodopa‐induced dyskinesias and continuous subcutaneous infusions of apomorphine: Results of a two‐year, prospective follow‐up , 2002, Movement disorders : official journal of the Movement Disorder Society.

[191]  Entacapone to Tolcapone Switch Study Investigators.  Entacapone to tolcapone switch: Multicenter double‐blind, randomized, active‐controlled trial in advanced Parkinson's disease , 2007, Movement disorders : official journal of the Movement Disorder Society.

[192]  K. Marder.  Cognitive impairment and dementia in Parkinson's disease , 2010, Movement disorders : official journal of the Movement Disorder Society.

[193]  Declining medication requirement in some patients with advanced Parkinson disease and dementia. , 2003, Clinical neuropharmacology.

[194]  M. Juncadella,et al.  Cognitive improvement after duodenal levodopa infusion in cognitively impaired Parkinson's disease patients , 2010, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[195]  A. Lees,et al.  Subcutaneous apomorphine in the treatment of Parkinson's disease. , 1990, Journal of neurology, neurosurgery, and psychiatry.

[196]  J. Jankovic,et al.  Long-term evaluation of deep brain stimulation of the thalamus. , 2006, Journal of neurosurgery.

[197]  L. Schiffer,et al.  Aromatic amino acids and modification of parkinsonism. , 1967, The New England journal of medicine.

[198]  N. Yanagisawa,et al.  Randomized, double‐blind study of pramipexole with placebo and bromocriptine in advanced Parkinson's disease , 2003, Movement disorders : official journal of the Movement Disorder Society.

[199]  Kapil D. Sethi,et al.  Bilateral deep brain stimulation versus best medical therapy for patients with advanced Parkinson’s disease , 2009, Current neurology and neuroscience reports.

[200]  G. Bono,et al.  Long-term experience with continuous duodenal levodopa–carbidopa infusion (Duodopa): report of six patients , 2009, Neurological Sciences.

[201]  H. Ross,et al.  A 10-year study of the incidence of and factors predicting dementia in Parkinson’s disease , 2000, Neurology.

[202]  D. Bowers,et al.  Cognition and mood in Parkinson's disease in subthalamic nucleus versus globus pallidus interna deep brain stimulation: The COMPARE Trial , 2009, Annals of neurology.

[203]  Y. Agid,et al.  Axial parkinsonian symptoms can be improved: the role of levodopa and bilateral subthalamic stimulation , 2000, Journal of neurology, neurosurgery, and psychiatry.

[204]  J. Obeso,et al.  Efficacy of deep brain stimulation of the subthalamic nucleus in Parkinson’s disease 4 years after surgery: double blind and open label evaluation , 2004, Journal of Neurology, Neurosurgery & Psychiatry.

[205]  Thomas D Parsons,et al.  Cognitive sequelae of subthalamic nucleus deep brain stimulation in Parkinson's disease: a meta-analysis , 2006, The Lancet Neurology.

[206]  D. Nyholm,et al.  Fluctuating functions related to quality of life in advanced Parkinson disease: effects of duodenal levodopa infusion , 2008, Acta neurologica Scandinavica.

[207]  Günther Deuschl,et al.  Rivastigmine for dementia associated with Parkinson's disease. , 2004, The New England journal of medicine.

[208]  S. Gauthier,et al.  The benefits of group occupational therapy for patients with Parkinson's disease. , 1987, The American journal of occupational therapy : official publication of the American Occupational Therapy Association.

[209]  K. Dujardin,et al.  A multicentre study on suicide outcomes following subthalamic stimulation for Parkinson's disease. , 2008, Brain : a journal of neurology.

[210]  C. Mariani,et al.  Randomized study of sertraline and low‐dose amitriptyline in patients with Parkinson's disease and depression: Effect on quality of life , 2006, Movement disorders : official journal of the Movement Disorder Society.

[211]  Dag Aarsland,et al.  Neuropsychiatric symptoms in Parkinson's disease , 2009, Movement disorders : official journal of the Movement Disorder Society.

[212]  Pablo Mir,et al.  Efficacy of long‐term continuous subcutaneous apomorphine infusion in advanced Parkinson's disease with motor fluctuations: A multicenter study , 2008, Movement disorders : official journal of the Movement Disorder Society.

[213]  Roberto Maestri,et al.  Rehabilitation treatment of gait in patients with Parkinson's disease with freezing: A comparison between two physical therapy protocols using visual and auditory cues with or without treadmill training , 2009, Movement disorders : official journal of the Movement Disorder Society.

[214]  M. Cenci,et al.  Glutamatergic mechanisms in the dyskinesias induced by pharmacological dopamine replacement and deep brain stimulation for the treatment of Parkinson's disease , 2012, Progress in Neurobiology.

[215]  Y. Agid,et al.  Treatment of End-of-Dose Wearing-Off in Parkinson’s Disease: Stalevo® (Levodopa/Carbidopa/Entacapone) and Levodopa/DDCI Given in Combination with Comtess®/Comtan® (Entacapone) Provide Equivalent Improvements in Symptom Control Superior to That of Traditional Levodopa/DDCI Treatment , 2005, European Neurology.

[216]  R. J. Leo,et al.  Movement disorders associated with the serotonin selective reuptake inhibitors. , 1996, The Journal of clinical psychiatry.